Drug Type Small molecule drug |
Synonyms + [2] |
Target |
Mechanism Raf kinase inhibitors(RAF serine/threonine protein kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H16ClFN6OS |
InChIKeyKVCQTKNUUQOELD-UHFFFAOYSA-N |
CAS Registry1446113-23-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 3 | SG | 18 Jan 2021 | |
Solid tumor | Phase 3 | TW | 18 Jan 2021 | |
Solid tumor | Phase 3 | DE | 18 Jan 2021 | |
Solid tumor | Phase 3 | PL | 18 Jan 2021 | |
Solid tumor | Phase 3 | NZ | 18 Jan 2021 | |
Solid tumor | Discovery | SG | 18 Jan 2021 | |
Solid tumor | Discovery | DE | 18 Jan 2021 | |
Solid tumor | Discovery | NZ | 18 Jan 2021 | |
Solid tumor | Discovery | TW | 18 Jan 2021 | |
Solid tumor | Discovery | PL | 18 Jan 2021 |
Phase 1 | BRAF mutation Solid Tumors BRAF mutation | 133 | Belvarafenib 300mg PO BID + Cobimetinib 20mg PO TIW | - | Positive | 23 Oct 2023 | |
Belvarafenib 300mg PO BID + Cobimetinib 20mg PO TIW (SC-A: BRAF fusion) | (iicahtpbsh) = sdxebdfzvj wemxqykrxi (xkafuhkhpt, 68.05 - 99.83) View more | ||||||
NCT03284502 (ESMO2021) Manual | Phase 1 | RAS/RAF mutation Solid Tumors NRAS Mutation | BRAF Mutation | 118 | cobimetinib+belvarafenib (NRASm melanoma) | (frrdmujaxo) = The most common treatment-emergent adverse events (TEAEs) were dermatitis acneiform (52.5%), diarrhea (28.0%), rash (27.1%), and increased CPK level (25.4%). injlzxdgox (nnbdicjaia ) | Positive | 16 Sep 2021 |
cobimetinib+belvarafenib (BRAFm melanoma) | |||||||
Phase 1 | 32 | (rsftxuepxh) = epzchmoyww rslewhfuef (fktqymwlxc ) | - | 28 May 2021 | |||
Phase 1 | - | oxjihvlhrz(cqxljlryut) = The most common treatment-emergent adverse events that occurred in more than 20% of patients were dermatitis acneiform fkmsueppdr (sempyrnfkk ) View more | Positive | 26 May 2019 | |||
NCT02405065 (ASCO2016) Manual | Phase 1 | 31 | (irucmcskbs) = One patient at 200mg BID experienced grade 3 skin rash hhsfeagybi (tezxxtohon ) View more | Positive | 05 Jun 2016 | ||
Phase 1 | - | xbstkybclf(sktkhsjnwu) = laklzbmamd tuvbfjssbi (cyfhvyfsqj ) View more | - | 01 Aug 2015 |